Latest News for our Portfolio Companies

News Page Pear Therapeutics

Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact…

Arboretum_JDJuly 28, 2021

Health Scholars News Page

Health Scholars’ Strengthens EMS Portfolio to Meet Virtual Learning Demand

Health Scholars is a cloud-based, virtual reality-ready clinical training platform with VR simulations, simulation center…

Arboretum_JDJuly 26, 2021

EQRx News Page

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration

Collaboration combines Exscientia’s leading AI-driven drug discovery capabilities and EQRx’s innovative development and commercialization model…

Arboretum_JDJune 25, 2021

Home Page News Page Pear Therapeutics

Pear Therapeutics to Become a Public Company

Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing prescription digital therapeutics (PDTs) to…

Arboretum_JDJune 22, 2021

Home Page Navv Systems News Page

Navv Systems Completes Seed Financing to Accelerate Commercialization

Navv Systems, a Southeastern Michigan-based healthcare technology company focused on hospital personnel location and equipment…

Arboretum_JDJune 9, 2021

Francis Medical Home Page News Page

Francis Medical Announces Positive Data from VAPOR 1 IDE Study

Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor…

Arboretum_JDJune 8, 2021

EQRx News Page

EQRx Reports Positive Phase 3 Result for Sugemalimab (PD-L1 program)

EQRx, a company committed to developing and delivering important new medicines at lower prices, along…

Arboretum_JDMay 28, 2021

Home Page Koya Medical News Page

Koya Medical Receives FDA Clearance for Compression Therapy System

Dayspring compression therapy system is now FDA cleared for treatment of lymphedema and venous diseases…

Arboretum_JDMay 26, 2021

EQRx News Page

EQRx Announces Results of Aumolertinib’s Phase III Trial

Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients…

Arboretum_JDMay 20, 2021

News

Success Begins Here

Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Health Scholars’ Strengthens EMS Portfolio to Meet Virtual Learning Demand

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration

Pear Therapeutics to Become a Public Company

Navv Systems Completes Seed Financing to Accelerate Commercialization

Francis Medical Announces Positive Data from VAPOR 1 IDE Study

EQRx Reports Positive Phase 3 Result for Sugemalimab (PD-L1 program)

Koya Medical Receives FDA Clearance for Compression Therapy System

EQRx Announces Results of Aumolertinib’s Phase III Trial

News & Insights

ARCHIVES